⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AZN News
AstraZeneca PLC
The Boston Globe to Host Rare Disease Summit
prnewswire.com
AZN
ASND
BMRA
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
businesswire.com
AZN
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
prnewswire.com
GILD
AZN
BMY
ABBV
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
prnewswire.com
ABBV
AMGN
AZN
BMY
GILD
JNJ
LLY
MRK
NVS
PFE
SNY
TMO
New "Hypertension Bites" Campaign Urges Adults to Prioritize Blood Pressure Control
prnewswire.com
AZN
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
prnewswire.com
AZN
Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica
globenewswire.com
SNY
AMGN
AZN
GSK
TEVA
CHKP
AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
businesswire.com
AZN
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
globenewswire.com
NVO
AZN
GSK
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
businesswire.com
AZN